SCHEMBL5658735

SCHEMBL5658735

Cn1ncc2cc(CC(N)C(=O)N3CCC(C4CCNCC4)CC3)ccc21

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNC P24863 5/20 0.45
CDK8 P49336 5/20 0.45
KDM1A O60341 4/20 0.44
OPRD1 P41143 3/20 0.42
ROCK2 O75116 1/20 0.41
CYP3A4 P08684 1/20 0.41
CTSC P53634 1/20 0.40
DPP4 P27487 1/20 0.39
F2 P00734 1/20 0.38
F10 P00742 1/20 0.38
PLG P00747 1/20 0.38
PLAU P00749 1/20 0.38
ST14 Q9Y5Y6 1/20 0.38
TNKS O95271 1/20 0.38
TNKS2 Q9H2K2 1/20 0.38
KDM2B Q8NHM5 1/20 0.38
CREBBP Q92793 1/20 0.37
HTR2A P28223 1/20 0.37
PASK Q96RG2 1/20 0.37
CDK19 Q9BWU1 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5658225 0.91 OPRD1 (0.44) CCNCCDK8KDM1AOPRD1ROCK2
SCHEMBL5658864 0.89 KDM1A (0.43) CCNCCDK8KDM1AOPRD1ROCK2
SCHEMBL5656506 0.89 KDM1A (0.41) CCNCCDK8KDM1AOPRD1ROCK2
SCHEMBL5660469 0.84 ROCK2 (0.39) OPRD1ROCK2CYP3A4DPP4F2
SCHEMBL5662346 0.83 KDM1A (0.44) CCNCCDK8KDM1AOPRD1ROCK2
SCHEMBL5661343 0.81 KDM1A (0.41) CCNCCDK8KDM1AOPRD1ROCK2
SCHEMBL5658992 0.80 CYP3A4 (0.62) ROCK2CYP3A4CTSC
SCHEMBL5659005 0.78 CYP3A4 (0.44) OPRD1ROCK2CYP3A4DPP4F2
SCHEMBL5658729 0.75 ROCK2 (0.47) ROCK2CYP3A4
SCHEMBL5658227 0.74 OPRK1 (0.39) OPRD1ROCK2CYP3A4DPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050227968-A1 Selected CGRP-antagonists process for preparing them and their use as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-10-13 US claimed
US-7205294-B2 Selected CGRP-antagonists process for preparing them and their use as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-04-17 US disclosed
US-20050227968-A1 Selected CGRP-antagonists process for preparing them and their use as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-10-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050227968-A1 Selected CGRP-antagonists process for preparing them and their use as pharmaceutical compositions BDKRB1, BDKRB2, CALCRL CCNC 2475/4885CDK8 4105/4885KDM1A 4125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.